EUCTR2016-002344-16-GB进行中（未招募）1 期
Targeted treatment early with etanercept (biosimilar) plus methotrexate or methotrexate with T2T care for DMARD-naïve early RA patients. A prospective, longitudinal cohort study with an embedded pilot randomised controlled trial to assess treatment rationalisation based on naïve CD4+ T-cell stratification. - TEEMS
niversity of Leeds0 个研究点目标入组 106 人开始时间: 2017年11月29日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 106
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Subject has a diagnosis of RA as defined by the new ACR/EULAR 2010 classification criteria
- •2. Newly diagnosed (within 12 weeks)
- •3. Active disease at screening (DAS28ESR =3.2)
- •4. Anti-citrillunated peptide protein antibody positive (ACPA)
- •5. Male & female subjects =18 years old.
- •6. DMARD-naïve
- •7. No use of intra-muscular/Intra-articular or oral corticosteroids 4 weeks prior to screening.
- •8. All male and female subjects biologically capable of having children must agree to use a reliable method of contraception for the duration of the study and 24 weeks after the end of the study period. Acceptable methods of contraception are surgical sterilisation, oral, implantable or injectable hormonal methods, intrauterine devices or barrier contraceptives.
- •9. Patients must have the capacity and be willing to provide written informed consent and comply with the requirements of the protocol.
- •10. Subjects deemed to be in good health with respect to clinical examination and screening blood tests, including full blood count (FBC), urea and electrolytes (U&E), and liver functions tests (LFT)- See below exclusion criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Use of any additional investigational medications or products within 4 weeks of screening.
- •2. Use of intramuscular, intra-articular or oral corticosteroids within 4 weeks prior to screening.
- •3. Pregnant/lactating women or planning pregnancy within 24 weeks of last protocol treatment
- •4. Planned surgery within the study period (requiring omission of study medication > 28 days).
- •5. The presence of other comorbidities, which the physician deems as significant to interfere with evaluation (musculoskeletal condition such as osteoarthritis & fibromyalgia).
- •6. Diagnosis of another inflammatory arthritis or conective tissue disease e.g. psoriatic arthritis or Ankylosing spondylitis, primary Sjogren’s syndrome, systemic sclerosis, systemic lupus erythematosus, polymyositis.
- •7. Patients with any ongoing or active infection or any major episode of severe infection requiring hospitalization or treatment with IV antibiotics within the preceding 4 weeks of screening and/or orally administered antibiotics in the preceding 2 weeks of screening.
- •8. Any contraindication to conventional DMARD’s and anti-TNF therapy
- •9. In receipt of a live vaccination within 4 weeks prior to screening
- •10.Patients with abnormal liver function at the time of screening or abnormal blood tests as shown by:
- •o Aminotransferase (AST)/alanine aminotransferase (ALT) >3x upper limit of normal (ULN), OR Bilirubin >51µmol/L
- •o Serum Creatinine >175 mmol/L, eGFR below 30ml/L/min/1.73m2
- •o Neutrophils <2000 x 10*6/L
- •o Platelets <125 x 109/L
- •o Haemoglobin <90 g/L for males and <85 g/L for females
研究者
相似试验
进行中（未招募）
4 期
Targeted treatment with etanercept plus methotrexate for early rheumatoid arthritis patients that have not received any treatment yet. The treatment is rationalised based on the normality of the T-cell stratification.Musculoskeletal DiseasesRheumatoid arthritisISRCTN17694963niversity of Leeds106
已完成
4 期
Effectiveness of Etanercept Biosimilar Initiating for Etanercept -Naive Patients, using Ultrasound, Clinical and Biomarker Assessments in Outcomes of Real World Therapy(ENPORT-NGSK Study):Study protocol for an interventional, multicenter, open-label, single-arm clinical trialRheumatoid arthritisJPRN-jRCTs071200054Kawakami Atsushi40
已完成
3 期
The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host DiseaseAcute Graft Versus Host DiseaseNCT00726375University of Michigan Rogel Cancer Center34
进行中（未招募）
不适用
Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgarisPsoriasis vulgaris (Plaque-Typ)MedDRA version: 9.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisEUCTR2008-000106-37-DEKlinik für Dermatologie und Allergologie der RUB, St. Josef Hospital
尚未招募
4 期
Prospective study on the effects of etanercept treatment in patients with rheumatoid arthritis who are naive for TNF-alpha blocking therapy or are non-responders to prior treatment with other anti-TNF-alpha medicatio1000381610023213rheumatoid arthritisNL-OMON32681Academisch Medisch Centrum200